Publicaciones en las que colabora con Borja Ibáñez Cabeza (109)

2024

  1. Apolipoprotein E-ϵ2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study

    Circulation Research, Vol. 134, Núm. 4, pp. 411-424

2023

  1. Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis

    Diabetes Care, Vol. 46, Núm. 11, pp. 2050-2057

  2. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

    Journal of the American College of Cardiology, Vol. 82, Núm. 22, pp. 2069-2083

  3. Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis

    Cardiovascular Diabetology, Vol. 22, Núm. 1

  4. Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

    The Lancet Healthy Longevity, Vol. 4, Núm. 9, pp. e487-e498

  5. Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study

    European heart journal, Vol. 44, Núm. 29, pp. 2698-2709

  6. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial

    European Journal of Heart Failure, Vol. 25, Núm. 3, pp. 373-385

2022

  1. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

    European heart journal, Vol. 43, Núm. 39, pp. 3826-3924

  2. Bone marrow activation in response to metabolic syndrome and early atherosclerosis

    European Heart Journal, Vol. 43, Núm. 19, pp. 1809-1828

  3. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  4. Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial

    European heart journal, Vol. 43, Núm. 38, pp. 3732-3745

  5. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  6. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  7. New 3-Dimensional Volumetric Ultrasound Method for Accurate Quantification of Atherosclerotic Plaque Volume

    JACC: Cardiovascular Imaging, Vol. 15, Núm. 6, pp. 1124-1135

  8. Polypill Strategy in Secondary Cardiovascular Prevention

    The New England journal of medicine, Vol. 387, Núm. 11, pp. 967-977

  9. Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

    eBioMedicine, Vol. 76

2021

  1. 2020 Update of the quality indicators for acute myocardial infarction: A position paper of the Association for Acute Cardiovascular Care: The study group for quality indicators from the ACVC and the NSTE-ACS guideline group

    European Heart Journal: Acute Cardiovascular Care, Vol. 10, Núm. 2, pp. 224-233

  2. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  3. Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

    Journal of the American College of Cardiology, Vol. 77, Núm. 22, pp. 2777-2791

  4. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8

    Journal of the American College of Cardiology, Vol. 78, Núm. 2, pp. 156-179